408 Followers on Owler

Spark Therapeutics

Spark Therapeutics develops gene therapies for the treatment of hemophilia and neurodegenerative diseases. Read more

Jeffrey D Marrazzo's photo - Co-Founder & CEO of Spark Therapeutics

Co-Founder & CEO

Jeffrey D Marrazzo

CEO Approval Rating

89/100

Founded:

2011

Status:

PrivateAcquisition Pending from F. Hoffmann-La Roche Ltd.

SPARK THERAPEUTICS TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

bluebird bio is one of Spark Therapeutics's top competitors. bluebird bio is a Public company that was founded in Cambridge, Massachusetts in 1992. bluebird bio is in the Biotechnology field. bluebird bio has 763 more employees vs. Spark Therapeutics.

uniQure is perceived as one of Spark Therapeutics's biggest rivals. uniQure was founded in 1998 in Amsterdam, Noord-Holland. uniQure competes in the Biotechnology industry. uniQure generates $55.6M less revenue than Spark Therapeutics.

Intellia is a top competitor of Spark Therapeutics. Intellia's headquarters is in Cambridge, Massachusetts, and was founded in 2014. Intellia competes in the Biotechnology field. Intellia generates 55% of Spark Therapeutics's revenue.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Lymphoseek a competitor of Spark Therapeutics?

Spark Therapeutics Acquisitions

No recent acquisitions found related to Spark Therapeutics

Spark Therapeutics Funding History

Since Spark Therapeutics was founded in 2011, it has participated in 4 rounds of funding. In total Spark Therapeutics has raised $377.8M. Spark Therapeutics' last funding round was on Dec 2015 for a total of $94.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Secondary Offering
Dec 2015
$94M
-
IPO
Jan 2015
$161M
-
Series B
May 2014
$72.8M
Series A
Oct 2013
$50M

Since Spark Therapeutics was founded in 2011, it has participated in 4 rounds of funding. In total Spark Therapeutics has raised $377.8M. Spark Therapeutics' last funding round was on Dec 2015 for a total of $94.0M

Spark Therapeutics Investments

No recent investments found related to Spark Therapeutics

Spark Therapeutics News

February 5, 2021Benzinga

Roche Unit Spark Therapeutics' Hemophilia A Gene Therapy Shows Durable Benefit In Early-Stage Study

Spark Therapeutics, a unit of Roche Holdings (OTC: RHHBY), has announced preliminary data from part o... See more »
February 1, 2021The Business Journals: Philadelphia

Spark Therapeutics doses first Pompe disease patient in study of experimental gene therapy

The company wants to enroll up to 20 patients with the rare, inherited disease for the study.... See more »
January 13, 2021The Business Journals: Philadelphia

Spark Therapeutics co-founder Dr. Katherine High takes C-suite role at North Carolina gene therapy company

In the wake of its potential $4 billion deal with Bayer, the firm is expanding its leadership team.... See more »
November 19, 2020mmm online

Spark Therapeutics adds chief strategy officer

Spark Therapeutics has appointed Michael Retterath as chief strategy officer. He joins the company fr... See more »
October 28, 2020The Business Journals: Philadelphia

Spark Therapeutics buys former Penn vivarium in Delaware County

The 17-acre property was originally built by DuPont and later occupied by the University of Pennsylva... See more »

Spark Therapeutics Press Releases

August 5, 2019firstwordpharma

report

Analysts have cautioned that an apparent change in stance from the US Federal Trade Commission that h... See more »
March 26, 2019GlobalNewswire

Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies

NEW YORK, March 26, 2019 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsin... See more »
May 8, 2018econotimes

Spark Therapeutics Reports First Quarter 2018 Financial Results and Recent Business Progress

PHILADELPHIA, May 08, 2018 -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy compa... See more »
January 4, 2018EconoTimes

Spark Therapeutics Announces Addition of Robert J. Perez to Board of Directors

Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging th... See more »
August 3, 2017GlobeNewswire

Spark Therapeutics Announces Pricing of $350.0 Million Public Offering

PHILADELPHIA, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics, Inc. ("Spark") (NASDAQ:ONCE) anno... See more »
August 2, 2017GlobeNewswire

Spark Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Progress

Preliminary interim data for SPK-8011 Phase 1/2 dose-escalation clinical trial in hemophilia A show i... See more »

Spark Therapeutics Videos

September 18, 2019Spark Therapeutics Vimeo Channel

"Paralympic Skier Danelle Umstead Teams Up with Eye Want 2 Know®" on VIMEO

Cast: Spark Therapeutics... See more »
September 9, 2019Spark Therapeutics Vimeo Channel

"Spark Therapeutics and Spark Program Announce New STEM-Focused Sponsorship" on VIMEO

Cast: Spark Therapeutics... See more »
August 2, 2018Spark Therapeutics Vimeo Channel

"We Are Spark" on VIMEO

Cast: Spark Therapeutics... See more »
December 13, 2017Spark Therapeutics Vimeo Channel

"Spark Therapeutics - B-roll Soundbites (2.5 min)" on VIMEO

B-roll selects for media use of Spark Therapeutics CEO, Jeff Marrazzo, and Spark Therapeutics Preside... See more »

Social Media

Spark Therapeutics Headquarters

3737 Market Street

Philadelphia, Pennsylvania19104

1-855-772-7589

Driving Directions »

Trending Companies

Spark Therapeutics Summary

ABOUT

Overview

Spark Therapeutics develops gene therapies for the treatment of hemophilia and neurodegenerative diseases. Spark Therapeutics was founded in 2011. Spark Therapeutics' headquarters is located in Philadelphia, Pennsylvania, USA 19104. It has raised 377....

CEO

Spark Therapeutics's Co-Founder & CEO, Jeffrey D Marrazzo, currently has an approval rating of 89%. Spark Therapeutics's primary competitors are bluebird bio, uniQure & Intellia.

Frequently Asked Questions about Spark Therapeutics

  1. When was Spark Therapeutics founded?

    Spark Therapeutics was founded in 2011
  2. Who is Spark Therapeutics's CEO?

    Spark Therapeutics's CEO is Jeffrey D Marrazzo
  3. How much revenue does Spark Therapeutics generate?

    Spark Therapeutics generates $93.5M in revenue
  4. How much funding does Spark Therapeutics have?

    Spark Therapeutics has historically raised $377.8M in funding
  1. Where is Spark Therapeutics's headquarters?

    Spark Therapeutics's headquarters is in Philadelphia Pennsylvania, USA
  2. How many employees does Spark Therapeutics have?

    Spark Therapeutics has 450 employees
  3. What sector does Spark Therapeutics operate in?

    Spark Therapeutics is in Biotechnology, Pharmaceuticals
  4. Who are Spark Therapeutics's competitors?

    Spark Therapeutics's top competitors are bluebird bio, uniQure, Intellia